DiaMedica Therapeutics (DMAC) Earnings Date & Reports

Key Takeaways

• DiaMedica Therapeutics (NASDAQ: DMAC), a clinical-stage biopharmaceutical company, is expected to report third-quarter 2026 results in mid-November 2026.
• As a development-stage drugmaker with no marketed products, the company is expected to post zero revenue and a net loss per share of roughly -$0.21, in line with its recent run-rate.
• Investor attention is centered less on the income statement and more on clinical progress, particularly enrollment and timing for the ReMEDy2 stroke trial.
• Management has signaled a key interim efficacy readout for ReMEDy2 in the first quarter of 2027, making near-term trial updates a major watch item.
• With about $43.5 million in cash and investments reported as of the prior quarter, the company has guided that its balance sheet can fund operations into 2027.
• For more detail on the company's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages on Tickeron.
• Investors looking for additional trading ideas can also explore Trending AI Robots for AI-driven market insights.

Earnings Context and Why It Matters

DiaMedica Therapeutics is a clinical-stage biotechnology company developing DM199, a recombinant protein candidate for acute ischemic stroke and related cardiovascular and kidney conditions. Because the company has no approved products, its quarterly results are effectively a snapshot of spending rather than sales, which makes this report meaningful mainly for what it reveals about clinical momentum and capital position. The upcoming third-quarter update arrives as the company's lead stroke study, ReMEDy2, advances toward an interim efficacy analysis expected in the first quarter of 2027. For investors, the report is a checkpoint on trial timelines, cash burn, and whether management's expense guidance remains on track ahead of a potentially pivotal data event.

Earnings Expectations

Wall Street does not expect DiaMedica to generate product revenue in the third quarter of 2026, reflecting its clinical-stage status. Consensus estimates point to a net loss of approximately -$0.21 per share for the period, a modest widening from the -$0.19 per share reported in the second quarter of 2026. The company has guided that quarterly losses could continue to expand modestly as its clinical programs advance, with management previously indicating roughly -$0.21 per share in the near term and slightly larger losses in subsequent quarters.

Rather than top-line figures, analysts and investors are likely to focus on research and development (R&D) expense trends, which surged roughly 41% year over year to about $8.2 million in the second quarter as trial activity accelerated. Other metrics to watch include the company's cash and investments balance and any updated commentary on cash runway, which management has said should support operations into 2027.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking clinical-stage names like DiaMedica or building watchlists across the biotech sector, the AI Screener offers a structured way to identify and monitor relevant opportunities.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter report has been shaped primarily by clinical catalysts rather than financial metrics. DiaMedica shares have historically shown relatively contained moves around earnings, consistent with a pre-revenue biotech whose quarterly prints carry limited headline value. The stock rose modestly following the second-quarter 2026 report, which matched consensus on the bottom line and highlighted positive early data from a late-onset preeclampsia study along with strong enrollment progress in ReMEDy2.

Key risk factors heading into this release include the pace of trial enrollment, any change in projected timelines for the interim analysis, and cash burn relative to the guided runway. Investors will also be watching for any indication that development costs are rising faster than anticipated, which could weigh on the stock even in the absence of new clinical data.

Forward Outlook and Key Factors to Monitor

Looking past the third-quarter print, the dominant catalyst for DiaMedica remains the ReMEDy2 Phase 2/3 trial in acute ischemic stroke, where an interim efficacy analysis is expected in the first quarter of 2027. Management has indicated the trial has surpassed the 85% enrollment milestone, and investors will want confirmation that enrollment completion and the data readout remain on schedule.

Beyond ReMEDy2, the company is advancing a late-onset preeclampsia program that recently delivered statistically significant blood pressure reduction in a clinical study. First patient dosing in a Canadian preeclampsia study is planned for the fourth quarter of 2026, providing another near-term milestone to monitor.

From a financial standpoint, watch the trajectory of R&D spending and the cash balance. DiaMedica ended the second quarter with roughly $43.5 million in cash and investments and has guided that this can fund operations into 2027. Any meaningful acceleration in expenses, or commentary suggesting a shorter runway, would be a key factor for investors to evaluate alongside the clinical timeline.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations